Relationship between medication adherence and treatment outcomes: The COMBINE study

Alcoholism: Clinical and Experimental Research

Volumn 32, Issue 9, 2008, Pages 1661-1669

  Zweben, Allen ^a   Pettinati, Helen M ^b   Weiss, Roger D ^c   Youngblood, Marston ^d   Cox, Christine E ^d   Mattson, Margaret E ^e   Gorroochurn, Prakash ^f   Ciraulo, Domenic ^g  

^a School of Social Work ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^f Department of Medicine   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acamprosate; Combined behavioral intervention; Medical management; Medication adherence; Naltrexone

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRINKING BEHAVIOR; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME; VOMITING;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (U.S.); TAURINE; TEMPERANCE; TREATMENT OUTCOME; UNITED STATES;

EID: 50849120037     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00743.x     Document Type: Article

References (32)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift RW, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral intervention for alcohol dependence: the COMBINE Study: a randomized controlled trial. JAMA 295 : 2003 2017.
2. Baros AM, Latham PK, Monk DH, Voronin K (2007) What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 31 : 596 603.
3. Carroll K (1997) Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Addict Behav 22 : 233 245.
4. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35 : 587 593.
5. Ciraulo DA (2007) Health effects of combine medications', Symposium on the Combine Study: Secondary Analyses. 30th Annual Scientific Meeting on Research Society on Alcoholism, Chicago, IL, p. 82.
6. Clifford PR, Maisto SA, Davis CM (2007) Alcohol treatment research assessment exposure subject reactivity effects: part 1. alcohol use and related consequences. J Stud Alcohol Drugs 68 : 519 528.
7. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J (2003) Compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6 : 566 573.
8. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S (1986) Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 256 : 1449 1355.
9. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Erich EW, Vivtrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 : 1617 1625.
10. Joe GW, Simpson DD, Hubbard RL (1991) Treatment predictors of tenure in methadone maintenance. J Subst Abuse 3 : 73 84.
11. Kranzler HR (2000) Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 35 : 537 547.
12. Miller WR (1996) Form 90: A Structured Assessment Interview for Drinking and Related Behaviors (Test Manual). National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
13. Miller WR (2004) Combined Behavioral Intervention Manual. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
14. Moos RH (2005) Iatrogenic effects of psychosocial interventions for substance use disorders: prevalence, predictors, prevention. Addiction 100 : 595 604.
15. Moos RH, Moos BS (2003) Long-term influence of duration and intensity of treatment of previously untreated individuals with alcohol use disorders. Addiction 98 : 325 327.
16. Moos R, Nichol A, Moos B (2002) Risk factors for symptom exacerbation among treated patients with substance use disorders. Addiction 97 : 75 85.
17. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O'Connor PG (2003) Initial and maintenance naltrexone treatment for alcohol dependence using primary vs. specialty care. Arch Intern Med 163 : 1695 1704.
18. Onken C, Van Kirk J, Kranzler H (2001) Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154 : 397 402.
19. Oslin DW, Lynch KL, Pettinati HM, Gariti P, Gelfand L, Wortman S, Dundon W, Dackis C, Volpicelli JR, O'Brien CP (in press). A placebo controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res.
20. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353 : 487 497.
21. Pettinati HM (2006) Improving medication adherence in alcohol dependence. J Clin Psychiatry 67 (Suppl. 14 23 29.
22. Pettinati HM, Volpicelli JR, Pierce JD, O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19 : 71 83.
23. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ (2004) Medical Management (MM) Treatment Manual. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD.
24. Pettinati H, Zweben A, Mattson M (Editors 2005) The combine study: conceptual, methodological and practical issues in conducting a clinical trial that combines pharmacological and behavioral treatments. J Stud Alcohol Suppl 15 : 1 207.
25. Rohsenow DJ, Colby SM, Monti PM, Swift RM, Martin RA, Mueller TI, Gordon A, Eaton CA (2000) Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 24 : 1542 1549.
26. Simpson DD, Joe G, Broom KM, Hiller ML, Knight K, Rowan-Szal GA (1997) Program diversity and treatment retention rates in the drug abuse treatment outcome study. Psychol Addict Behav 11 : 279 293.
27. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods (Allen J, Litten RZ eds pp 41 72. Humana Press, Totowa, NJ.
28. Stout RL (2007) Advancing the analysis of treatment process. Addiction 102 : 1539 1545.
29. Volpicelli JR, Rhimes KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54 : 737 742.
30. Weiss RD (2004) Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 99 : 1382 1392.
31. Zhang Z, Friedman PD, Gerstein DR (2003) Does retention matter? Treatment duration and improvement in drug use Addiction 98 : 673 684.
32. Zweben A, Zuckoff A (2002). Treatment preparation, induction and adherence. in Motivational Interviewing (2nd ed. Miller WR, Rollnick S eds), pp. 299 319. Guilford Press, New York.